Evidence map›Paper›PMID 30065964›Full record

ArticleBioengineering & translational medicine2018

TGF-β-responsive CAR-T cells promote anti-tumor immune function.

Andrew J Hou, ZeNan L Chang, Michael H Lorenzini, Eugenia Zah, Yvonne Y Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioengineering & translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2024
    Article
  18. Review
  19. Review
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Andrew J HouDept. of Chemical and Biomolecular Engineering University of California, Los Angeles Los Angeles CA 90095.
ZeNan L ChangDept. of Chemical and Biomolecular Engineering University of California, Los Angeles Los Angeles CA 90095.
Michael H LorenziniDept. of Bioengineering University of California, Los Angeles Los Angeles CA 90095.
Eugenia ZahDept. of Chemical and Biomolecular Engineering University of California, Los Angeles Los Angeles CA 90095.
Yvonne Y ChenDept. of Chemical and Biomolecular Engineering University of California, Los Angeles Los Angeles CA 90095.ORCID 0000-0002-5583-119X
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Xinmin Li · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
UCLA-Caltech Medical Scientist Training ProgramT32GM008042 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI AJIJOLA, OLUJIMI A, DAWSON, DAVID WAYNE · 1985 to 2023
$29.9M
UC BRAID Center for Accelerated Innovation COVID-19 diagnostic project developmentU54HL119893 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PALAZZOLO, MICHAEL J · 2013 to 2020
$18.3M
Biotechnology Training in Biomedical Sciences and EngineeringT32GM067555 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GU, ZHEN · 2005 to 2019
$2.8M
Engineering of computational receptors and gene circuits for T-cell immunotherapyDP5OD012133 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHEN, YVONNE YU-HSUAN · 2012 to 2016
$1.7M
Engineering robust adoptive T-cell cancer therapy by rewiring TGF-beta signalingF30CA183528 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHANG, ZENAN L · 2014 to 2016
$134k
NCATS NIH HHS UL1 TR001881NCI NIH HHS F30 CA183528NCI NIH HHS P30 CA016042NHLBI NIH HHS U54 HL119893NIGMS NIH HHS T32 GM067555NIH HHS DP5 OD012133
6 · The paper itself

Abstract

A chimeric antigen receptor (CAR) that responds to transforming growth factor beta (TGF-β) enables the engineering of T cells that convert this immunosuppressive cytokine into a potent T-cell stimulant. However, clinical translation of TGF-β CAR-T cells for cancer therapy requires the ability to productively combine TGF-β responsiveness with tumor-targeting specificity. Furthermore, the potential concern that contaminating, TGF-β?producing regulatory T (Treg) cells may preferentially expand during TGF-β CAR-T cell manufacturing and suppress effector T (Teff) cells demands careful evaluation. Here, we demonstrate that TGF-β CAR-T cells significantly improve the anti-tumor efficacy of neighboring cytotoxic T cells. Furthermore, the introduction of TGF-β CARs into mixed T-cell populations does not result in the preferential expansion of Treg cells, nor do TGF-β CAR-Treg cells cause CAR-mediated suppression of Teff cells. These results support the utility of incorporating TGF-β CARs in the development of adoptive T-cell therapy for cancer.

Indexed as

adoptive T‐cell therapychimeric antigen receptorimmunosuppressionimmunotherapyTGF‐β

Identifiers

PMID30065964
PMCPMC6063867
OpenAlexW2807108630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.